Why is Tilray stock down today? Key support levels to watch

Traders Union
All News
Stocks
Tilray drops 3.32% today to $4.52

Highlights

Tilray Brands introduced Tilray Medical cannabis flower in the UK through Lyphe Clinic and Lyphe Dispensary, increasing direct-to-patient access in the regulated market.
The company expanded its beverage portfolio with a new low-dose cannabis seltzer multipack targeting a broader consumer segment.
Shares of Tilray closed at $4.52 after falling 3.32%, with technical signals indicating a bearish short- and long-term trend and an expected range of $4.35 to $4.70 in the next 2 to 3 trading days.

UK market entry and product launches offset by sustained selling pressure

Tilray Brands has launched its Tilray Medical-branded cannabis flower products in the UK through partnerships with Lyphe Clinic and Lyphe Dispensary, establishing a direct-to-patient distribution channel to the regulated UK medicinal cannabis market, according to Globenewswire. This move expands Tilray's commercial footprint and is likely to improve access for patients seeking cannabis-derived therapies, thereby increasing the company's revenue opportunities outside North America. Separately, Tilray Brands introduced a new low-dose cannabis seltzer in a multipack format, which extends its beverage line-up and serves to broaden the group's consumer base, as noted by Kalkinemedia, though price action has remained under broader selling pressure.

Bearish bias as price fails at key moving averages and momentum signals weakness

TLRY remains below its MA-20 ($4.63) and MA-50 ($4.59) on the hourly chart, confirming that intraday price is struggling to regain key short-term levels, while the MA-200 on the daily timeframe at $7.22 marks a significant long-term resistance. Immediate resistance is defined by the Ichimoku Kijun at $4.68, with support at $4.35. Momentum readings point to a challenging environment: the MACD gives a Sell signal, the ADX is Neutral, while RSI at 45.18 and CCI on Sell both suggest modest weakness but not an oversold setup. Stoch RSI is Neutral, Bull/Bear Power remains on Sell, and the Awesome Oscillator supports a bearish bias, with sellers dominating intraday trading.

Downside risk persists as TLRY stays in defined range amid seller control

Looking ahead to the next 2–3 trading days, TLRY is expected to remain confined within the $4.35 to $4.70 range, consistent with recent volatility and resistance at the Ichimoku Kijun. If price reclaims $4.68, a short-term bullish scenario could unfold with a quick push higher, though this outcome is less probable (21% up vs 79% down). Conversely, a break below $4.35 would reinforce the prevailing downtrend and likely drive further losses. Under the baseline scenario, TLRY is set to remain near current levels as sellers continue to control the short-term direction.

Viktoras Karapetjanc, expert at Traders Union, sees Tilray's continued global expansion as a constructive driver, especially with the UK direct-to-patient launch signaling stronger international positioning. He notes that, despite the positive momentum on the fundamental side, price action stays under clear technical pressure below key averages. Karapetjanc believes short-term recovery is possible if $4.68 is reclaimed, though the odds remain against an immediate bullish reversal. "Tilray's international initiatives offer long-term strength, but near-term sentiment remains cautious until price stabilizes above resistance levels."

Earlier, analysts noted that TLRY remained under persistent selling pressure, with technical readings suggesting continued caution for traders. The latest developments reinforce this cautious backdrop, highlighting $4.35 as a key support level to monitor for potential downside risk in the coming sessions.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.